Polkowska Aleksandra, Toropainen Maija, Ollgren Jukka, Lyytikäinen Outi, Nuorti J Pekka
School of Health Sciences, University of Tampere, Lääkärinkatu, Tampere, Finland.
Department of Infectious Diseases, National Institute for Health and Welfare (THL), Mannerheimintie, Helsinki, Finland.
BMJ Open. 2017 Jun 6;7(5):e015080. doi: 10.1136/bmjopen-2016-015080.
Bacterial meningitis remains an important cause of morbidity and mortality worldwide. Its epidemiological characteristics, however, are changing due to new vaccines and secular trends. Conjugate vaccines against type b and (10-valent) were introduced in 1986 and 2010 in Finland. We assessed the disease burden and long-term trends of five common causes of bacterial meningitis in a population-based observational study.
A case was defined as isolation of , , , or from cerebrospinal fluid and reported to national, population-based laboratory surveillance system during 1995-2014. We evaluated changes in incidence rates (Poisson or negative binomial regression), case fatality proportions (χ) and age distribution of cases (Wilcoxon rank-sum).
During 1995-2014, and accounted for 78% of the total 1361 reported bacterial meningitis cases. accounted for 4% of cases (92% of isolates were non-type b). During the study period, the overall rate of bacterial meningitis per 1 00 000 person-years decreased from 1.88 cases in 1995 to 0.70 cases in 2014 (4% annual decline (95% CI 3% to 5%). This was primarily due to a 9% annual reduction in rates of (95% CI 7% to 10%) and 2% decrease in (95% CI 1% to 4%). The median age of cases increased from 31 years in 1995-2004 to 43 years in 2005-2014 (p=0.0004). Overall case fatality proportion (10%) did not change from 2004 to 2009 to 2010-2014.
Substantial decreases in bacterial meningitis were associated with infant conjugate vaccination against pneumococcal meningitis and secular trend in meningococcal meningitis in the absence of vaccination programme. Ongoing epidemiological surveillance is needed to identify trends, evaluate serotype distribution, assess vaccine impact and develop future vaccination strategies.
细菌性脑膜炎仍是全球发病和死亡的重要原因。然而,由于新疫苗和长期趋势,其流行病学特征正在发生变化。1986年和2010年在芬兰分别引入了针对b型和(10价)的结合疫苗。我们在一项基于人群的观察性研究中评估了细菌性脑膜炎五种常见病因的疾病负担和长期趋势。
病例定义为从脑脊液中分离出、、、或,并在1995 - 2014年期间报告给全国性的基于人群的实验室监测系统。我们评估了发病率的变化(泊松或负二项回归)、病死率比例(χ)以及病例的年龄分布(Wilcoxon秩和检验)。
在1995 - 2014年期间,和占报告的1361例细菌性脑膜炎病例总数的78%。占病例的4%(92%的分离株为非b型)。在研究期间,每10万人年的细菌性脑膜炎总体发病率从1995年的1.88例降至2014年的0.70例(年下降4%(95%CI 3%至5%))。这主要是由于发病率每年下降9%(95%CI 7%至10%)以及发病率下降2%(95%CI 1%至4%)。病例的中位年龄从1995 - 2004年的31岁增加到2005 - 2014年的43岁(p = 0.0004)。2004年至2009年以及2010 - 2014年期间总体病死率比例(10%)没有变化。
细菌性脑膜炎的大幅下降与针对肺炎球菌脑膜炎的婴儿结合疫苗接种以及在没有疫苗接种计划的情况下脑膜炎球菌脑膜炎的长期趋势有关。需要持续的流行病学监测来确定趋势、评估血清型分布、评估疫苗影响并制定未来的疫苗接种策略。